A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
Clinical trial NCT03474679 · COMPLETED
Trial details
- NCT number
- NCT03474679
- Sponsor
- Janssen Pharmaceutical K.K.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-01
- Primary completion
- 2021-11-29
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.